METHODS FOR TREATMENT AND DIAGNOSIS OF PSYCHIATRIC DISORDERS

• US 20100316626A1
• Filed: 08/10/2007
• Published: 12/16/2010
• Est. Priority Date: 08/11/2006
• Status: Abandoned Application

• Current Assignee: United States Department Of Health And Human Services (Government of the United States of America)
• Original Assignee: Government of the United States of America
• Inventors: Buonanno, Andres
• Application Number:
  US12/377,025
• Publication Number:
  US 20100316626A1
• Time in Patent Office: Days
• US Class Current: 424/130.1
• CPC Class Codes: A61K 31/517 ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 38/179 for growth factors; for growth regulators
• CPC Class Codes: A61K 38/1883 Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: G01N 2800/30 Psychoses; Psychiatry
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/5058 Neurological cells

Abstract

A method for preventing or treating a psychiatric disorder in a mammalian subject is provided. A method for preventing or treating a psychiatric disorder in a mammalian subject is provided which comprises administering to the subject a modulator of ErbB receptor signaling in an amount effective to reduce or eliminate the psychiatric disorder in the subject or to prevent its occurrence or recurrence. A method for diagnosis of a psychiatric disorder in a mammalian subject is provided.

Claims

1. A method for treating a psychiatric disorder in a mammalian subject comprising administering to the subject a modulator of ErbB receptor signaling pathway in an amount effective to reduce or eliminate the psychiatric disorder in the subject or to prevent its occurrence or recurrence.

2. The method of claim 1 wherein the modulator is a small chemical compound, an antisense RNA, an siRNA, shRNA, antibody, peptide or peptide mimetic.

3. The method of claim 1 wherein ErbB receptor signaling occurs by ligand activation.

4. The method of claim 1 wherein the modulator is an inhibitor of ErbB tyrosine kinase or an antagonist of ErbB receptor signaling pathway.

5. The method of claim 1 wherein the modulator is an activator of ErbB tyrosine kinase or an agonist of ErbB receptor signaling pathway.

6. The method of claim 4 wherein the inhibitor or the antagonist modulates induction or expression of long term potentiation in the mammalian subject.

7. The method of claim 5 wherein the activator or the agonist modulates induction or expression of long term potentiation in the mammalian subject.

8. The method of claim 1 wherein the psychiatric disorder is schizophrenia, bipolar depression, autism, or attention deficit disorder.

9. The method of claim 1, wherein the modulator of ErbB receptor signaling is a modulator of dopaminergic transmission signaling.

10. The method of claim 9, wherein the modulator of ErbB receptor signaling affects an activity of dopamine D2 type receptor signaling.

11. The method of claim 9 wherein the modulator of dopaminergic transmission signaling modulates induction or expression of long term potentiation in the mammalian subject.

12. The method of claim 1, wherein the modulator of ErbB receptor signaling is a modulator of one or more ADAM proteases.

13. The method of claim 1, wherein the modulator of ErbB receptor signaling is a modulator of gamma-secretase.

14. The method of claim 1, wherein the modulator of ErbB receptor signaling is a modulator of glutamatergic transmission signaling.

15. The method of claim 1 further comprising administering to the subject a modulator of glutamatergic transmission signaling.

16. The method of claim 1 further comprising administering to the subject a modulator of dopaminergic transmission signaling.

17. The method of claim 1 further comprising administering to the subject a modulator of ADAM protease activity.

18. The method of claim 1 further comprising administering to the subject a modulator of gamma secretase activity.

20. The method of claim 1 wherein the ErbB receptor modulator is a modulator of cholinergic transmission signaling.

21. The method of claim 1 wherein the ErbB receptor is ErbB1 receptor, ErbB2 receptor, ErbB3 receptor, or ErbB4 receptor.

22. The method of claim 21 wherein the ErbB receptor is ErbB4 receptor.

23. The method of claim 3 wherein the ligand is an EGF-like motif-containing ligand.

24. The method of claim 23 wherein the EGF-like motif-containing ligand is neuregulin.

25. The method of claim 24 wherein the neuregulin is neuregulin 1, neuregulin 2, neuregulin 3, or neuregulin 4.

26. A method for identifying a modulator of signaling in cells via an ErbB receptor signaling pathway comprising,

contacting a test compound with a cell-based assay system comprising a cell expressing ErbB receptor capable of signaling responsiveness to a ligand and expressing dopamine receptor capable of signaling responsiveness to dopamine,

providing the ligand to the assay system in an amount selected to be effective to modulate ErbB receptor signaling, and

detecting an effect of the test compound on ErbB receptor signaling in the assay system, effectiveness of the test compound in the assay being indicative of the modulation.

27. The method of claim 26 wherein the ligand is an EGF-like motif-containing ligand.

28. The method of claim 27 wherein the ligand is neuregulin 1, neuregulin 2, neuregulin 3, or neuregulin 4.

29. The method of claim 26 wherein the ErbB receptor is an ErbB1 receptor, ErbB2 receptor, ErbB3 receptor, or ErbB4 receptor.

30. The method of claim 26 wherein the cells are hippocampal cells, neuronal cells, glial cells, brain tissue, olfactory epithelial cells, or neuroepithelial cells.

31. The method of claim 26 wherein the detecting step further comprises measuring theta-pulse stimuli depotentiation of long term potentiation in the cell in response to ligand signaling via ErbB receptor.

32. The method of claim 31 wherein the detecting step further comprises modulating depotentiation of long term potentiation in response to theta pulse stimuli by administration of the compound in the cellular assay.

33. The method of claim 26 wherein the detecting step further comprises measuring dopamine receptor signaling in response to dopamine.

34. The method of claim 33 wherein the detecting step further comprises measuring modulation of dopamine receptor signaling and modulation of long term potentiation in response to theta pulse stimuli by administration of the compound in the cellular assay.

35. The method of claim 26, further comprising screening a compound to treat a a psychiatric disorder in a mammalian subject by detecting an effect of the test compound on ErbB receptor signaling in the assay system, effectiveness of the test compound in the assay being indicative of efficacy of treatment in the mammalian subject.

36. A method for identifying a modulator of signaling in cells via an ErbB receptor signaling pathway comprising,

contacting a test compound with a tissue-based assay system comprising a tissue expressing ErbB receptor capable of signaling responsiveness to a ligand,

providing the ligand to the assay system in an amount selected to be effective to modulate ErbB receptor signaling, and

detecting an effect of the test compound on ErbB receptor signaling in the assay system by measuring a change in amplitude or frequency of gamma oscillatory activity, effectiveness of the test compound in the assay being indicative of the modulation.

37. The method of claim 36 wherein the detecting step further comprises measuring a change in frequency or power of kainate-induced or carbachol-induced gamma oscillatory activity.

38. The method of claim 36 wherein the tissue based assay comprises brain tissue.

39. A method for screening a compound to treat a psychiatric disorder in a mammalian subject comprising,

contacting a test compound with a cell-based assay system comprising a cell expressing ErbB receptor capable of signaling responsiveness to a ligand and expressing D2 type receptor capable of signaling responsiveness to dopamine,

providing the ligand to the assay system in an amount selected to be effective to modulate ErbB receptor signaling, and

detecting an effect of the test compound on ErbB receptor signaling in the assay system, effectiveness of the test compound in the assay being indicative of efficacy of treatment in the mammalian subject.

40. The method of claim 39 wherein the psychiatric disorder is schizophrenia, attention deficit disorder, bipolar depression, or autism.

41. A method for diagnosing a psychiatric disorder in a mammalian subject comprising

isolating lymphocytes expressing NRG gene and ErbB receptor gene,

analyzing splice variants of NRG mRNA or ErbB mRNA, and

determining a predisposition to a psychiatric disorder on the basis of splice variants of NRG mRNA or ErbB mRNA.

42. The method of claim 41, wherein the NRG splice variants encode type I, type II, type III or type IV neuregulin-1.

43. The method of claim 41 wherein the NRG gene encodes neuregulin 1, neuregulin 2, neuregulin 3, or neuregulin 4.

44. The method of claim 41 wherein the ErbB receptor gene encodes ErbB1 receptor, ErbB2 receptor, ErbB3 receptor, or ErbB4 receptor.

45. The method of claim 41 wherein the psychiatric disorder is schizophrenia, attention deficit disorder, bipolar depression, or autism.

46. A method for diagnosing a psychiatric disorder in a mammalian subject comprising

isolating neural cells expressing NRG gene and ErbB receptor gene,

analyzing polymorphisms of the NRG gene or the ErbB receptor gene, and

determining a predisposition to a psychiatric disorder on the basis of polymorphisms of the NRG-1 gene or the ErbB4 receptor gene.

47. The method of claim 46 wherein the polymorphism of NRG gene or ErbB receptor gene is a single nucleotide polymorphism.

48. The method of claim 46 wherein the NRG gene encodes neuregulin 1, neuregulin 2, neuregulin 3, or neuregulin 4.

49. The method of claim 46 wherein the ErbB receptor gene encodes ErbB1 receptor, ErbB2 receptor, ErbB3 receptor, or ErbB4 receptor.

50. The method of claim 46 wherein the psychiatric disorder is schizophrenia, attention deficit disorder, bipolar depression, or autism.

51. The method of claim 46 wherein the neural cell is a hippocampal cell, neuronal cell, glial cell, brain tissue, olfactory epithelial cell, or neuroepithelial cell.